EGFR and non-small cell lung carcinoma: Targeting this pathway represents a potentially effective therapeutic strategy for restoring the sensitivity to EGFR-TKIs in resistant NSCLC tumors, ultimately improving the therapeutic effectiveness and outcome of these patients.